Long‐Term Medication Profiles in Parkinson's Disease under Subthalamic Deep Brain Stimulation: A Controlled Study
Movement Disorders Clinical Practice2024Vol. 11(7), pp. 855–860
Citations Over TimeTop 18% of 2024 papers
Christoph Theyer, Vincent Beliveau, Florian Krismer, Marina Peball, Katherina Mair, Beatrice Heim, Atbin Djamshidian, Stefan Kiechl, Wilhelm Eisner, Sabine Eschlböck, Gregor K. Wenning, Peter Willeit, Klaus Seppi, Werner Poewe, Philipp Mahlknecht
Abstract
In PD patients, chronic STN-DBS was associated with a lower LEDD compared with control patients over 14 years.
Related Papers
- → Placement of Deep Brain Stimulators into the Subthalamic Nucleus or Globus pallidus internus: Technical Approach(2002)209 cited
- → Deep brain stimulation of the subthalamic nucleus improves sense of well‐being in parkinson's disease(2012)20 cited
- → Subthalamic nucleus deep brain stimulation for the treatment of secondary dystonia: A case series and review of literature(2017)7 cited
- → Post-Mortem Analysis of Parkinson’s Disease Brains After 11 and 12 Years of Deep Brain Stimulation of the Subthalamic Nucleus(2022)1 cited
- → PO061 / #228 LONG-TERM OUTCOME OF SUBTHALAMIC NUCLEUS DEEP BRAIN STIMULATION FOR PARKINSON’S DISEASE: 10 YEARS AND BEYOND(2022)